Key Insights

Highlights

Treatment Research

1 treatments under study, led by 68ganotaantiher2 Vhh1

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03924466Phase 2Unknown

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

Showing all 1 trials

Research Network

Common Treatments

  • 68ganotaantiher2 Vhh11

Active Sponsors

  • Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.1
  • Kom Op Tegen Kanker1
  • Universitair Ziekenhuis Brussel1

Top Investigators

Related Conditions

  • Urothelial Carcinoma1
  • Endometrial Cancer1
  • Colorectal Cancer1
  • Gastric Cancer1
  • Salivary Gland Cancer1

Activity Timeline